{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIfG0JsJDA","lastupdate":"2020-08-10T00:00:00.000Z","update_date":"2020-08-10T00:00:00.000Z","lastModified":"Jun 29, 2022","active":1,"confidence_score":85,"confidence_score_reason":"not claimed, video or image","urlname":"immunobrain-checkpoint","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$88l3vLQzxyLWv0cS3tQQWA7GmcvYXj32v56L6QVYZtjqbvRcWvMkYd","name":"ImmunoBrain Checkpoint","oneliner":"Disease-modifying Immunotherapies for Neurodegenerative Disorders","registrar":"515211860","website":"https://immunobrain.com/","careerspage":"","founded_month":2,"founded_year":2015,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/10319109","instagram":""},"social":["https://www.linkedin.com/company/10319109"],"flattenedsociallinks":"https://www.linkedin.com/company/10319109","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":19,"patent":0,"raised":0,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Immuno Brain","Immuno-Brain","IBC","IMMUNOBRAIN THERAPIES"],"about":"ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company focused on developing a pipeline of disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. \r\n\r\nIBCs novel approach to the treatment of neurodegeneration is based on years of innovative scientific discoveries made by Prof. Michal Schwartz of the Weizmann Institute of Science. IBCs lead programs are being developed for the treatment of Alzheimers disease, employing a novel approach of blocking the PD-1/PD-L1 immune checkpoint pathway.\r\n\r\nIn June 2017, Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, obtained the rights to IBCs research into treatment for Alzheimers disease. As part of the agreement, Lundbeck will provide the funding for, as well as participate in, additional research that will allow the identification of potential therapies for clinical trials. \r\n\r\nLundbeck also obtained minority ownership of IBC and has the exclusive option to take over the rights and activities relating to this technology at a later date.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"eb702fa7-0028-4d47-8054-bfdeab2d1e38","city":"Ness Ziona","type":null,"address":"Pinhas Sapir St 3, Ness Ziona, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"jsFwNDjCqpgIGkH2fD32WtJesxUgFj8iXCBSKSOQVi87ebOgsZ8Vsn","date":"Oct 21, 2025","link":"https://www.prnewswire.com/il/news-releases/pioneering-physician-scientist-dr-francis-s-collins-joins-immunobrain-board-of-directors-302590340.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"management changes","round":null,"company":"ImmunoBrain","layoffs":null,"summary":"ImmunoBrain, a clinical-stage biopharmaceutical company, announced the appointment of Dr. Francis S. Collins to its board of directors. Dr. Collins, a renowned physician-scientist and former director of the National Institutes of Health, brings extensive experience in biomedical research. His appointment is expected to bolster ImmunoBrains efforts in developing novel immunotherapies for neurodegenerative diseases, particularly Alzheimers. The company is currently conducting a Phase 1b clinical trial for its lead drug candidate, IBC-Ab002, which targets an inhibitory immune checkpoint pathway. Supported by grants from the National Institute on Aging and the Alzheimers Association, the trial is showing encouraging interim results, with topline data expected in Q1 2026.","partners":null,"customers":null,"eventType":null,"investors":["National Institute on Aging","Alzheimers Association"],"confidence":9,"key_topics":["Alzheimers","immunotherapy","clinical trial","board appointment","neurodegenerative"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Management Changes  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fmMxFL0eYi2DmyiswiJBfR90e6ug6Wuv4CL6BZtCFyvPoO1Y9bsu29","news_summary":"/PRNewswire/ -- ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced the...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"JnVP0EK15jyvWWLZgoLZVenvKlKgoGsGzTf5F2XuORW9683yoeqhf2","date":"Sep 10, 2025","link":"https://www.prnewswire.com/il/news-releases/immunobrain-appoints-rochelle-walensky-md-mph-to-its-board-of-directors-302552977.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"management changes","round":null,"company":"ImmunoBrain Checkpoint Inc.","layoffs":null,"summary":"ImmunoBrain Checkpoint Inc., a clinical-stage biopharmaceutical company, has appointed Dr. Rochelle Walensky to its board of directors. The company is conducting a Phase 1b clinical trial for its lead drug candidate, IBC-Ab002, aimed at treating Alzheimers disease and other forms of dementia. Dr. Walensky, with a background in infectious diseases and public health, brings valuable expertise to the company. The appointment is seen as a positive step in advancing ImmunoBrains mission to develop innovative therapies for neurodegenerative diseases. The company is supported by grants from the National Institute on Aging and the Alzheimers Association, with topline data from the trial expected in Q1 2026.","partners":["NU Advisory Partners"],"customers":[],"eventType":null,"investors":[],"confidence":9,"key_topics":["neurodegeneration","Alzheimers","immunotherapy","clinical trial","board appointment"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Management Changes  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aDX5ypjHAc1M2rdj2chJwznuMFwPU0okn2YRxXSubzonOLLbgFXC7d","news_summary":"/PRNewswire/ -- ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced the...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"50bf1dd1-cc77-4a06-ade2-fa301ba140ce","date":"Jun 8, 2017","link":"https://alzheimersnewstoday.com/2017/06/08/lundbeck-obtains-rights-to-research-immune-checkpoint-pathways-in-alzheimers-disease/","source":"alzheimersnewstoday.com","visible":1,"analysis":{"tags":"research","company":"Lundbeck","layoffs":null,"summary":"Lundbeck has obtained the rights to IBCs research on treatment for Alzheimers disease, specifically targeting immune checkpoint pathways. The research focuses on blocking the PD-1/PD-L1 pathway, which has shown promise in cancer treatment and could potentially be extended to neurodegenerative diseases. Lundbeck will provide funding for additional research and has the option to take over the rights and activities relating to this technology in the future. The partnership with IBC is part of Lundbecks strategy to supplement its own research activities.","partners":"IBC","customers":null,"investors":null,"confidence":8,"key_topics":["Alzheimers","immune checkpoint pathways","research","treatment","Lundbeck"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9nfGt3Qq3qwYx0rfelFq6CPCq4D4onedzE3TCHcoysmMcKptIXIMWa","news_summary":"Lundbeck Obtains Rights to Research that Targets Immune Checkpoint...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":3,"techcommunityinvolvement":null,"mediagallery":[],"tags":["brain-disorder","biopharmaceutical","neuroscience","alzheimers-disease","biotechnology","neurology","immunology","pharma-companies","immunotherapy","pharmaceuticals"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA"],"technologysuccessstory":[{"date":"2015-02-01","name":"Novel disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways","tags":["cns-disorders","neurology","immunotherapy"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/yeda_tto_logo_fbd2f2eb-6016-11e8-8318-41fdcbb0dda6","university_logo":"/image_cloud/yeda_institution_logo_fbd2f2eb-6016-11e8-8318-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":[],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":1,"lastfunding":"Undisclosed","totalrounds":1,"fundingstage":"Seed","totalfunding":"Undisclosed","publicinvestors":1,"lastpublicfunding":0,"totalpublicrounds":1,"totalpublicfunding":0},"team":[{"name":"Prof. Michal Shwartz","email":"michal@ibcheckpoint.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPv-iPAKDA","bounced":true,"claimed":0,"founder":1,"urlname":"prof-michal-shwartz","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg-4GE3QgM","position":"Founder","last_name":"Shwartz","claimtoken":"bc472b86673e27f9d3802a51da39cf85659610c08921d8d5131bc5cf81196534","first_name":"Prof. Michal","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/michal-schwartz-567a2919/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-08-10 06:41:11.000000","initials":"PS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eti Yoles","email":"eti@ibcheckpoint.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoIfGzIYLDA","bounced":true,"claimed":0,"founder":0,"urlname":"eti-yoles","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgm87arAkM","position":"Senior Executive VP, Development & Operations","last_name":"Yoles","claimtoken":"b4bd0e5b09a44e52e2d7c67be8de0b14ec1e6a1d7fb75d80b8a9bbdbbade69dd","first_name":"Eti","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/eti-yoles-b9697813/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-08-10 06:41:13.000000","initials":"EY","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Carol David","email":"carol@ibcheckpoint.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4PHHrowKDA","bounced":true,"claimed":0,"founder":0,"urlname":"carol-david","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgydKsgAoM","position":"VP Manufacturing & Product Development","last_name":"David","claimtoken":"e2c769f363e190a24faa688138b89f04bcf888a9735db7748a9b9115c0cab601","first_name":"Carol","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/carol-david-b285a6132/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"CD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Kuti Baruch","email":"kuti@ibcheckpoint.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPvCgJoKDA","bounced":true,"claimed":0,"founder":0,"urlname":"kuti-baruch","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgx6GjjAkM","position":"Head of R&D","last_name":"Baruch","claimtoken":"33931826d7d30f6c6ef21cedd44113a28e056c516a44ef84183f9c0729223895","first_name":"Kuti","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/kutibaruch/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-08-10 06:41:08.000000","initials":"KB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPW8rMQKDA","fullname":"Lena Rogovina"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwN25h58KDA","fullname":"Vered Waxman"},"biverifydate":"2020-02-27T00:00:00.000Z","crunchbaseid":"immunobrain-checkpoint","lastupdator":"Asaph Wagner","lastupdator_email":"asaphwagner@hotmail.com","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2019-02-25T00:00:00.000Z","biverification":"Vered Waxman","sectorverification":"Lena Rogovina","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtez1CQw","date":"Oct 2017","amount":"Undisclosed","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"SBI JI Innovation Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/sbi-ji-innovation-fund","logokey":"$l5XLL7u3lPaEq6FIDtyqX4jY9ExGEQDE2YB5yvBXJ3j9wNR3iQzAyK","tagline":null,"urlname":"/investor_page/sbi-ji-innovation-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJvW_-EKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"078dae41-60a9-4c97-bb08-ea5c16059622","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$l5XLL7u3lPaEq6FIDtyqX4jY9ExGEQDE2YB5yvBXJ3j9wNR3iQzAyK","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":0,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"2/2015","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"ImmunoBrain Checkpoint","logourl":"https://storage.googleapis.com/clean-finder-353810/$88l3vLQzxyLWv0cS3tQQWA7GmcvYXj32v56L6QVYZtjqbvRcWvMkYd","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$88l3vLQzxyLWv0cS3tQQWA7GmcvYXj32v56L6QVYZtjqbvRcWvMkYd","seoabout":"ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company focused on developing a pipeline of disease-modifying immunotherapies for neurological disorder...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Biomaterials & Tissue Engineering","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Biomaterials & Tissue Engineering#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Biomaterials & Tissue Engineering#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"},{"title":"Biomaterials & Tissue Engineering","key":"0-0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Biomaterials & Tissue Engineering"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Biotechnology","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"},{"title":"Pharmaceuticals","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Biomaterials & Tissue Engineering","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development","Biomaterials & Tissue Engineering"],"coreTechnology":["Biologicals"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Biotechnology","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtez1CQw","date":"Oct 2017","amount":"Undisclosed","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"SBI JI Innovation Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/sbi-ji-innovation-fund","logokey":"$l5XLL7u3lPaEq6FIDtyqX4jY9ExGEQDE2YB5yvBXJ3j9wNR3iQzAyK","tagline":null,"urlname":"/investor_page/sbi-ji-innovation-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJvW_-EKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"078dae41-60a9-4c97-bb08-ea5c16059622","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$l5XLL7u3lPaEq6FIDtyqX4jY9ExGEQDE2YB5yvBXJ3j9wNR3iQzAyK","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":0,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}